Eli Lilly’s ongoing platform technology evaluation agreement with Peptron, extended through October 7, 2026, remains limited to non-exclusive joint research on SmartDepot microsphere formulations for peptide candidates, including GLP-1 assets and newer CNS targets. No commercial licensing, technology transfer, or binding deal granting Lilly rights to the long-acting delivery platform has been announced despite nearly two years of in-vivo studies and initial validation. Traders assign an 87.5% implied probability to “No” because Lilly has simultaneously advanced competing long-acting technologies such as Camurus’ FluidCrystal and signed separate high-value licensing deals elsewhere, while Peptron focuses on its own PT403 candidate and manufacturing expansion. The short window to resolution leaves little room for a surprise announcement before the cutoff.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · UpdatedEli Lilly licenses Peptron’s SmartDepot by October 7?
Eli Lilly licenses Peptron’s SmartDepot by October 7?
13% chance
$11,414 Vol.
$11,414 Vol.
Oct 6, 2026
13% chance
$11,414 Vol.
$11,414 Vol.
Oct 6, 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s ongoing platform technology evaluation agreement with Peptron, extended through October 7, 2026, remains limited to non-exclusive joint research on SmartDepot microsphere formulations for peptide candidates, including GLP-1 assets and newer CNS targets. No commercial licensing, technology transfer, or binding deal granting Lilly rights to the long-acting delivery platform has been announced despite nearly two years of in-vivo studies and initial validation. Traders assign an 87.5% implied probability to “No” because Lilly has simultaneously advanced competing long-acting technologies such as Camurus’ FluidCrystal and signed separate high-value licensing deals elsewhere, while Peptron focuses on its own PT403 candidate and manufacturing expansion. The short window to resolution leaves little room for a surprise announcement before the cutoff.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Market Opened: May 5, 2026, 8:02 PM ET
Volume
$11,414End Date
Oct 7, 2026Market Opened
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s ongoing platform technology evaluation agreement with Peptron, extended through October 7, 2026, remains limited to non-exclusive joint research on SmartDepot microsphere formulations for peptide candidates, including GLP-1 assets and newer CNS targets. No commercial licensing, technology transfer, or binding deal granting Lilly rights to the long-acting delivery platform has been announced despite nearly two years of in-vivo studies and initial validation. Traders assign an 87.5% implied probability to “No” because Lilly has simultaneously advanced competing long-acting technologies such as Camurus’ FluidCrystal and signed separate high-value licensing deals elsewhere, while Peptron focuses on its own PT403 candidate and manufacturing expansion. The short window to resolution leaves little room for a surprise announcement before the cutoff.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Volume
$11,414End Date
Oct 7, 2026Market Opened
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly’s ongoing platform technology evaluation agreement with Peptron, extended through October 7, 2026, remains limited to non-exclusive joint research on SmartDepot microsphere formulations for peptide candidates, including GLP-1 assets and newer CNS targets. No commercial licensing, technology transfer, or binding deal granting Lilly rights to the long-acting delivery platform has been announced despite nearly two years of in-vivo studies and initial validation. Traders assign an 87.5% implied probability to “No” because Lilly has simultaneously advanced competing long-acting technologies such as Camurus’ FluidCrystal and signed separate high-value licensing deals elsewhere, while Peptron focuses on its own PT403 candidate and manufacturing expansion. The short window to resolution leaves little room for a surprise announcement before the cutoff.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions